# Ipamorelin: The Research, the Stacks, and the Honest Limits > Ipamorelin is a selective growth-hormone secretagogue, most often studied as one half of a GHRH-analog stack. A vetted, plain-English digest of the cited literature. An ornamented but evidence-first reading of what the literature establishes for ipamorelin on its own, and where the popular combination protocols are running ahead of the data. ## In plain language Ipamorelin is a small lab-made peptide — a chain of five amino acids — that tells the pituitary gland (a pea-sized gland under the brain) to release a pulse of growth hormone. Its claim to fame is being tidy about it: in animal studies it raised growth hormone without meaningfully raising the stress hormone cortisol or the milk hormone prolactin, which the older peptides in its family did [1]. People rarely study it by itself. The far more common research picture pairs it with a second peptide called CJC-1295, because the two push the same hormone through two different doors. Here is the honest part: ipamorelin has never been approved as a medicine anywhere, its one human efficacy trial did not work [3], and the popular [ipamorelin cjc-1295](/with-cjc-1295) protocols have never been tested as a combination in a real trial. This site reads the studies plainly, separates what was shown in ipamorelin alone from what was shown in its chemical cousins, and keeps every number tied to its source. What people report — including the downsides — is on [the effects page](/effects). ## What ipamorelin actually is, and why it is studied in pairs Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide and a selective agonist of the ghrelin receptor — the GHS-R1a, the same receptor the body's natural "hunger hormone" ghrelin uses [1]. Activating that receptor on pituitary somatotrophs triggers growth-hormone release. Its founding 1998 characterization established the defining trait the whole field returns to: in rat pituitary cells, anaesthetised rats and conscious swine it released growth hormone potently (swine ED50 = 2.3 nmol/kg, against 3.9 nmol/kg for GHRP-6), yet did not lift cortisol above the level seen with growth-hormone-releasing hormone even at doses more than two-hundred-fold above its growth-hormone threshold [1]. The reason ipamorelin appears in nearly every protocol beside a second compound is mechanistic. Ipamorelin works through the ghrelin-receptor door; growth-hormone-releasing hormone analogs such as CJC-1295 work through a separate receptor and a separate signal. Combine the two and the growth-hormone response is larger than either alone — a class-level synergy demonstrated across rats, lambs, mice and humans for the peptide family [9][10][15]. That is the [ipamorelin cjc-1295](/with-cjc-1295) rationale in one sentence: two doors, one hormone, a bigger pulse. ## What the human record shows — and where it stops The human file on ipamorelin itself is short and largely negative. One pharmacokinetic study in healthy men characterized a terminal half-life of roughly two hours after intravenous dosing, with a single growth-hormone pulse peaking about forty minutes later [2]. The only published Phase 2 efficacy trial — 114 adults given ipamorelin after bowel surgery to restart the gut — missed its primary endpoint: time to first tolerated meal was 25.3 hours on ipamorelin against 32.6 hours on placebo, a difference that did not reach significance (p=0.15) [3]. No Phase 3 trial followed and no indication was ever approved. Everything more ambitious — the anti-aging, fat-loss and muscle claims — rests on mechanism and short rodent studies, not on controlled human outcomes. In adult female rats, subcutaneous ipamorelin dose-dependently raised the rate of long-bone growth without changing systemic IGF-1 [4]. In a 2024 ferret study it blunted chemotherapy-driven weight loss by about 24 percent through a peripheral route [5]. These are real, cited findings in animals. They are not human results, and this site never dresses them as such. ## Monotherapy and combination are not the same evidence The single most important distinction on this site is between what ipamorelin has been shown to do by itself and what its chemical relatives have shown in combination. Ipamorelin's own evidence is specific and limited: a defining selectivity profile [1], a roughly two-hour human half-life [2], one failed human efficacy trial [3], and rodent findings on bone growth [4] and chemotherapy weight loss [5]. The combination evidence — the case for stacking a ghrelin-receptor agonist with a GHRH analog — is real and reproducible, but it was largely built with GHRP-6, GHRP-2, hexarelin and CJC-1295, not with ipamorelin in head-to-head trials [9][10][7]. So when a claim rests on "the stack," it usually rests on class-level pharmacology extrapolated to ipamorelin, not on a study of ipamorelin in that stack. The combination itself has never been tested as a product for any outcome. This digest keeps that line bright on every page rather than letting the strength of the class evidence quietly transfer to the specific compound. ## How to read this digest The pages divide the territory cleanly. [Ipamorelin research](/research) covers the mechanism and the key studies, separating ipamorelin's own data from class-level evidence. [Ipamorelin effects](/effects) gathers what the research-use community reports — the sleep, the flushing, the appetite — clearly labelled as anecdote, alongside the cited safety cautions that genuinely matter. The dosage page logs the doses administered in the studies, in third person and never as advice. The combination page reads the CJC-1295 stack on its own terms, and a separate comparison weighs ipamorelin against sermorelin. A note on the name. "Legit" here is a posture toward the evidence, not a verdict on any seller. We grade the quality of the studies, flag where marketing has outrun them, and decline to endorse any vendor or product. The point of a vetted digest is to make the strong claims and the thin ones equally visible — and to keep [every figure pinned to its source](/references). --- A vetted, combination-stacks-first reading of the ipamorelin record — the selective GH pulse and the CJC-1295 pairing examined in measured detail, ipamorelin's own studies kept distinct from its chemical relatives, and the popular protocols held to the trial that was never run on them; no clinic behind the name, no seller endorsed, and nothing here dosed, prescribed, or sold.